Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Patel, Priti"" wg kryterium: Autor


Tytuł :
Erratum: Fyn tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates antiglioma immune responses.
Autorzy :
Comba A; Department of Neurosurgery, Ann Arbor, Michigan.; Department of Cell and Developmental Biology, Ann Arbor, Michigan.; Rogel Cancer Center, Ann Arbor, Michigan.
Dunn PJ; Department of Neurosurgery, Ann Arbor, Michigan.; Department of Cell and Developmental Biology, Ann Arbor, Michigan.; Rogel Cancer Center, Ann Arbor, Michigan.
Argento AE; Department of Neurosurgery, Ann Arbor, Michigan.; Department of Cell and Developmental Biology, Ann Arbor, Michigan.; Rogel Cancer Center, Ann Arbor, Michigan.
Kadiyala P; Department of Neurosurgery, Ann Arbor, Michigan.; Department of Cell and Developmental Biology, Ann Arbor, Michigan.; Rogel Cancer Center, Ann Arbor, Michigan.
Ventosa M; Department of Neurosurgery, Ann Arbor, Michigan.; Department of Cell and Developmental Biology, Ann Arbor, Michigan.; Rogel Cancer Center, Ann Arbor, Michigan.
Patel P; Department of Neurosurgery, Ann Arbor, Michigan.; Department of Cell and Developmental Biology, Ann Arbor, Michigan.; Rogel Cancer Center, Ann Arbor, Michigan.
Zamler DB; Department of Neurosurgery, Ann Arbor, Michigan.; Department of Cell and Developmental Biology, Ann Arbor, Michigan.; Rogel Cancer Center, Ann Arbor, Michigan.
Nunez FJ; Department of Neurosurgery, Ann Arbor, Michigan.; Department of Cell and Developmental Biology, Ann Arbor, Michigan.; Rogel Cancer Center, Ann Arbor, Michigan.
Zhao L; Department of Biostatistics, Ann Arbor, Michigan.
Castro MG; Department of Neurosurgery, Ann Arbor, Michigan.; Department of Cell and Developmental Biology, Ann Arbor, Michigan.; Rogel Cancer Center, Ann Arbor, Michigan.
Lowenstein PR; University of Michigan Medical School, Ann Arbor, Michigan.
Pokaż więcej
Źródło :
Neuro-oncology [Neuro Oncol] 2021 Aug 02; Vol. 23 (8), pp. 1413.
Typ publikacji :
Published Erratum
Tytuł :
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Autorzy :
Byrd JC; The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Hillmen P; St James's University Hospital, Leeds, UK.
Ghia P; Università Vita-Salute San Raffaele, Milano, Italy.; IRCCS Ospedale San Raffaele, Milano, Italy.
Kater AP; Amsterdam University Medical Centers, University of Amsterdam, on behalf of Hovon, Amsterdam, the Netherlands.
Chanan-Khan A; Mayo Clinic Jacksonville, Jacksonville, FL.
Furman RR; Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY.
O'Brien S; Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA.
Yenerel MN; Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Illés A; University of Debrecen, Debrecen, Hungary.
Kay N; Mayo Clinic Rochester, Rochester, MN.
Garcia-Marco JA; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Mato A; University of Pennsylvania, Philadelphia, PA.
Pinilla-Ibarz J; Moffitt Cancer Center, Tampa, FL.
Seymour JF; Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia.
Lepretre S; Centre Henri Becquerel, Rouen, France.; Normandie University UNIROUEN, Rouen, France.
Stilgenbauer S; Internal Medicine III, University of Ulm, Ulm, Germany.
Robak T; Medical University of Lodz, Lodz, Poland.
Rothbaum W; Acerta, South San Francisco, CA.
Izumi R; Acerta, South San Francisco, CA.
Hamdy A; Acerta, South San Francisco, CA.
Patel P; AstraZeneca, South San Francisco, CA.
Higgins K; AstraZeneca, South San Francisco, CA.
Sohoni S; AstraZeneca, South San Francisco, CA.
Jurczak W; Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Jul 26, pp. JCO2101210. Date of Electronic Publication: 2021 Jul 26.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase 1b study.
Autorzy :
Strati P; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.
De Vos S; Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
Ruan J; Division of Hematology and Medical Oncology,Meyer Cancer Center, Weill Cornell Medicine, New York, NY.
Maddocks KJ; Division of Hematology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH.
Flowers CR; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Winship Cancer Institute of Emory University, Atlanta, GA.
Rule S; Department of Haematology, Plymouth University Medical School, Plymouth.
Patel P; AstraZeneca, South San Francisco, CA.
Xu Y; AstraZeneca, South San Francisco, CA.
Wei H; AstraZeneca, South San Francisco, CA.
Frigault MM; AstraZeneca, South San Francisco, CA.
Calvo R; AstraZeneca, Gaithersburg, MD.
Dyer MJS; Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester. .
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2021 Jul 08. Date of Electronic Publication: 2021 Jul 08.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Prognostic Role of Receptor Tyrosine Kinase-Like Orphan Receptors in Intestinal-Type Gastric Cancer.
Autorzy :
Nema R; Department of Biochemistry, All India Institute of Medical Sciences (AIIMS) Bhopal, Saket Nagar, Bhopal, India.
Patel P; Department of Biochemistry, All India Institute of Medical Sciences (AIIMS) Bhopal, Saket Nagar, Bhopal, India.
Kumar A; Department of Biochemistry, All India Institute of Medical Sciences (AIIMS) Bhopal, Saket Nagar, Bhopal, India.
Pokaż więcej
Źródło :
Asian Pacific journal of cancer prevention : APJCP [Asian Pac J Cancer Prev] 2021 Jul 01; Vol. 22 (7), pp. 2125-2134. Date of Electronic Publication: 2021 Jul 01.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
Autorzy :
Byrd JC; The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Furman RR; Division of Hematology and Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY.
Martin P; Division of Hematology and Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY.
O'Brien S; Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA.
Brown JR; Dana-Farber Cancer Institute, Boston, MA.
Stephens DM; University of Utah Huntsman Cancer Institute, Salt Lake City, UT.
Barrientos JC; Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY.
Devereux S; College Hospital, NHS Foundation Trust Denmark Hill, London, United Kingdom.
Hillmen P; St James's University Hospital, Leeds, United Kingdom.
Pagel JM; Swedish Cancer Institute, Seattle, WA.
Hamdy A; AstraZeneca, South San Francisco, CA; and.
Izumi R; AstraZeneca, South San Francisco, CA; and.
Patel P; AstraZeneca, South San Francisco, CA; and.
Wang MH; AstraZeneca, South San Francisco, CA; and.
Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Wierda WG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Pokaż więcej
Źródło :
Blood [Blood] 2021 Jun 17; Vol. 137 (24), pp. 3327-3338.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.
Autorzy :
Izutsu K; National Cancer Center Hospital, Tokyo, Japan.
Ando K; Tokai University Hospital, Isehara, Japan.
Ennishi D; Okayama University Hospital, Okayama, Japan.
Shibayama H; Osaka University Hospital, Osaka, Japan.
Suzumiya J; Shimane University Hospital, Izumo, Japan.
Yamamoto K; Aichi Cancer Center Hospital, Nagoya, Japan.
Ichikawa S; Tohoku University Hospital, Sendai, Japan.
Kato K; Kyushu University Hospital, Fukuoka, Japan.
Kumagai K; Chiba Cancer Center, Chiba, Japan.
Patel P; Acerta Pharma, South San Francisco, CA, USA.
Iizumi S; AstraZeneca K.K., Tokyo, Japan.
Hayashi N; AstraZeneca K.K, Osaka, Japan.
Kawasumi H; AstraZeneca K.K., Tokyo, Japan.
Murayama K; AstraZeneca K.K, Osaka, Japan.
Nagai H; National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2021 Jun; Vol. 112 (6), pp. 2405-2415. Date of Electronic Publication: 2021 May 07.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Benzamides/*administration & dosage
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Lymphoma, Mantle-Cell/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Pyrazines/*administration & dosage
Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Benzamides/adverse effects ; Benzamides/pharmacokinetics ; Drug Administration Schedule ; Female ; Headache/chemically induced ; Headache/epidemiology ; Humans ; Japan ; Leukemia, Lymphocytic, Chronic, B-Cell/blood ; Lymphoma, Mantle-Cell/blood ; Male ; Middle Aged ; Neoplasm Recurrence, Local/blood ; Purpura/chemically induced ; Purpura/epidemiology ; Pyrazines/adverse effects ; Pyrazines/pharmacokinetics ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Opportunities to Improve Antibiotic Prescribing in Outpatient Hemodialysis Facilities: A Report From the American Society of Nephrology and Centers for Disease Control and Prevention Antibiotic Stewardship White Paper Writing Group.
Autorzy :
Apata IW; Centers for Disease Control and Prevention, Atlanta, MD; Division of Renal Medicine, Emory University School of Medicine, Atlanta, MD. Electronic address: .
Kabbani S; Centers for Disease Control and Prevention, Atlanta, MD.
Neu AM; Johns Hopkins School of Medicine, Baltimore, MD.
Kear TM; M. Louise Fitzpatrick College of Nursing, Villanova University, Villanova, PA.
D'Agata EMC; Brown University, Providence, RI.
Levenson DJ; Partners in Nephrology and Endocrinology, Pittsburgh, PA.
Kliger AS; Yale School of Medicine, New Haven, CT.
Hicks LA; Centers for Disease Control and Prevention, Atlanta, MD.
Patel PR; Centers for Disease Control and Prevention, Atlanta, MD.
Pokaż więcej
Źródło :
American journal of kidney diseases : the official journal of the National Kidney Foundation [Am J Kidney Dis] 2021 May; Vol. 77 (5), pp. 757-768. Date of Electronic Publication: 2020 Oct 10.
Typ publikacji :
Journal Article
MeSH Terms :
Antimicrobial Stewardship*
Infection Control*
Renal Dialysis*
Anti-Bacterial Agents/*therapeutic use
Kidney Failure, Chronic/*therapy
Sepsis/*prevention & control
Staphylococcal Infections/*drug therapy
beta-Lactams/*therapeutic use
Ambulatory Care ; Ambulatory Care Facilities ; Blood Culture/standards ; Centers for Disease Control and Prevention, U.S. ; Clinical Audit ; Decision Support Systems, Clinical ; Formative Feedback ; Humans ; Interdisciplinary Communication ; Nephrology ; Patient Transfer/standards ; Quality Improvement ; Societies, Medical ; Staphylococcus aureus ; United States
Czasopismo naukowe
Tytuł :
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.
Autorzy :
Furman RR; Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA. .
Byrd JC; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Owen RG; St. James's University Hospital, Leeds, UK.
O'Brien SM; Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA, USA.
Brown JR; Dana-Farber Cancer Institute, Boston, MA, USA.
Hillmen P; St. James's University Hospital, Leeds, UK.
Stephens DM; University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
Chernyukhin N; AstraZeneca, South San Francisco, CA, USA.
Lezhava T; AstraZeneca, South San Francisco, CA, USA.
Hamdy AM; AstraZeneca, South San Francisco, CA, USA.
Izumi R; AstraZeneca, South San Francisco, CA, USA.
Patel P; AstraZeneca, South San Francisco, CA, USA.
Baek M; AstraZeneca, South San Francisco, CA, USA.
Christian B; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Dyer MJS; The Ernest and Helen Scott Haematological Research Institute, University Hospitals of Leicester NHS Trust, Leicester, UK.
Streetly MJ; Guy's Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Sun C; National Heart, Lung, and Blood Institute, Bethesda, MD, USA.
Rule S; Plymouth University Medical School, Plymouth, UK.
Wang M; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ghia P; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy.
Jurczak W; Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland.
Pagel JM; Swedish Cancer Institute, Seattle, WA, USA.
Sharman JP; Willamette Valley Cancer Institute/US Oncology, Eugene, OR, USA.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Apr 27. Date of Electronic Publication: 2021 Apr 27.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Willingness to Receive a COVID-19 Vaccination Among Incarcerated or Detained Persons in Correctional and Detention Facilities - Four States, September-December 2020.
Autorzy :
Stern MF
Piasecki AM
Strick LB
Rajeshwar P
Tyagi E
Dolovich S
Patel PR
Fukunaga R
Furukawa NW
Pokaż więcej
Źródło :
MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2021 Apr 02; Vol. 70 (13), pp. 473-477. Date of Electronic Publication: 2021 Apr 02.
Typ publikacji :
Journal Article
MeSH Terms :
COVID-19 Vaccines/*administration & dosage
Patient Acceptance of Health Care/*psychology
Prisoners/*psychology
Vaccination/*psychology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; COVID-19/epidemiology ; COVID-19/prevention & control ; Disease Outbreaks/prevention & control ; Female ; Humans ; Male ; Middle Aged ; Prisoners/statistics & numerical data ; Prisons ; Socioeconomic Factors ; Surveys and Questionnaires ; United States/epidemiology ; Young Adult
Czasopismo naukowe
Tytuł :
Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Autorzy :
Rogers KA; The Ohio State University, Columbus, OH. .
Thompson PA; MD Anderson Cancer Center, Houston, TX.
Allan JN; Weill Cornell Medicine, New York, NY.
Coleman M; Weill Cornell Medicine, New York, NY.
Sharman JP; Willamette Valley Cancer Institute, Eugene, OR.
Cheson BD; Georgetown University Hospital, Washington, DC.
Jones D; The Ohio State University, Columbus, OH.
Izumi R; Acerta Pharma, South San Francisco, CA.
Frigault MM; Acerta Pharma, South San Francisco, CA.
Quah C; Acerta Pharma, South San Francisco, CA.
Raman RK; Acerta Pharma, South San Francisco, CA.
Patel P; Acerta Pharma, South San Francisco, CA.
Wang MH; Acerta Pharma, South San Francisco, CA.
Kipps TJ; UC San Diego Moores Cancer Center, San Diego, CA.
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2021 Mar 18. Date of Electronic Publication: 2021 Mar 18.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Outbreak of hepatitis B and hepatitis C virus infections associated with a cardiology clinic, West Virginia, 2012-2014.
Autorzy :
Tressler SR; West Virginia Bureau for Public Health, Charleston, West Virginia.
Del Rosario MC; West Virginia Bureau for Public Health, Charleston, West Virginia.
Kirby MD; Beckley-Raleigh County Health Department, Beckley, West Virginia.
Simmons AN; West Virginia Bureau for Public Health, Charleston, West Virginia.
Scott MA; West Virginia Bureau for Public Health, Charleston, West Virginia.
Ibrahim S; West Virginia Bureau for Public Health, Charleston, West Virginia.
Forbi JC; Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia.
Thai H; Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia.
Xia GL; Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia.
Lyman M; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Collier MG; Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia.
Patel PR; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Bixler D; West Virginia Bureau for Public Health, Charleston, West Virginia.
Pokaż więcej
Źródło :
Infection control and hospital epidemiology [Infect Control Hosp Epidemiol] 2021 Mar 01, pp. 1-6. Date of Electronic Publication: 2021 Mar 01.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
Autorzy :
Kreitman RJ; Clinical Immunotherapy Section, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD, 20892, USA. .
Dearden C; The Royal Marsden Hospital, Downs Road, Sutton, England, UK.
Zinzani PL; Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, Bologna, Italia.; Istituto di Ematologia, 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università Degli Studi, Bologna, Italia.
Delgado J; Hospital Clinic Barcelona, IDIBAPS, Barcelona, Spain.
Robak T; Medical University of Łódź and Copernicus Memorial Hospital, Pabianicka 62, 90-001, Łódź, Poland.
le Coutre PD; Charité - Universitätsmedizin Berlin, Charitépl. 1, 10117, Berlin, Germany.
Gjertsen BT; Haukeland University Hospital and University of Bergen, Jonas Lies vei 65, 5021, Bergen, Norway.
Troussard X; Hospital Center University of Caen Normandie, Avenue de La Côte de Nacre, 14000, Caen, France.
Roboz GJ; Weill Cornell Medical College, The New York Presbyterian Hospital, 525 E 68th St, New York, NY, USA.
Karlin L; Hôpital Lyon Sud, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69310 Pierre-Bénite, Lyon, France.
Gladstone DE; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 401 N Broadway, Baltimore, MD, USA.
Kuptsova-Clarkson N; AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA.
Liu S; Acerta Pharma (AstraZeneca), 121 Oyster Point Blvd, South San Francisco, CA, USA.
Patel P; Acerta Pharma (AstraZeneca), 121 Oyster Point Blvd, South San Francisco, CA, USA.
Rotolo F; Innate Pharma, 117 Avenue de Luminy, BP 30191, 13276, Marseille, France.
Mitry E; Innate Pharma, 117 Avenue de Luminy, BP 30191, 13276, Marseille, France.
Pastan I; Clinical Immunotherapy Section, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD, 20892, USA.
Giles F; Developmental Therapeutics Consortium, 175 E Delaware Pl #7204, Chicago, IL, USA.
Pokaż więcej
Corporate Authors :
Study 1053 investigators
Źródło :
Journal of hematology & oncology [J Hematol Oncol] 2021 Feb 24; Vol. 14 (1), pp. 35. Date of Electronic Publication: 2021 Feb 24.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Can intravenous antimicrobial start data reported to the National Healthcare Safety Network determine appropriateness of antibiotic use in hemodialysis patients?
Autorzy :
Patel PR; Centers for Disease Control and Prevention, Atlanta, Georgia.
Novosad SA; Centers for Disease Control and Prevention, Atlanta, Georgia.
Apata IW; Centers for Disease Control and Prevention, Atlanta, Georgia.; Emory University School of Medicine, Atlanta, Georgia.
Pokaż więcej
Źródło :
Infection control and hospital epidemiology [Infect Control Hosp Epidemiol] 2021 Feb 09, pp. 1-2. Date of Electronic Publication: 2021 Feb 09.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Impact of supplemental individual verbal defense on confidence, engagement, and performance in a team-based learning therapeutics course.
Autorzy :
Allen JM; Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, 6550 Sanger Road, Suite 420G, Orlando, FL 32827, United States; Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, FL 32827, United States. Electronic address: .
Egelund EF; Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, 580 W. 8th Street, Jacksonville, FL 32209, United States. Electronic address: .
Santevecchi BA; Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, 1225 Center Drive, Gainesville, FL 32610, United States. Electronic address: .
Venugopalan V; Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, 1225 Center Drive, Gainesville, FL 32610, United States. Electronic address: .
Whalen K; Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, 1225 Center Drive, Gainesville, FL 32610, United States. Electronic address: .
Patel PN; Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, 1225 Center Drive, Gainesville, FL 32610, United States. Electronic address: .
Pokaż więcej
Źródło :
Currents in pharmacy teaching & learning [Curr Pharm Teach Learn] 2021 Feb; Vol. 13 (2), pp. 152-158. Date of Electronic Publication: 2020 Oct 09.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Almotriptan
Autorzy :
Sidhu G; Avalon University School of Medicine
Patel P; Un of Florida College of Pharmacy
Pokaż więcej
Źródło :
2021 Jan.
Typ publikacji :
Recenzja
Recenzja
Tytuł :
Zolmitriptan
Autorzy :
Abram JA; Florida International University Herbert Wertheim College of Medicine
Patel P; Un of Florida College of Pharmacy
Pokaż więcej
Źródło :
2021 Jan.
Typ publikacji :
Recenzja
Recenzja
Tytuł :
Optimizing Peritoneal Dialysis-Associated Peritonitis Prevention in the United States: From Standardized Peritoneal Dialysis-Associated Peritonitis Reporting and Beyond.
Autorzy :
Perl J; Division of Nephrology, St. Michael's Hospital and the Keenan Research Center in the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada .
Fuller DS; Arbor Research Collaborative for Health, Ann Arbor, Michigan.
Boudville N; Medical School, University of Western Australia, Perth, Australia.
Kliger AS; Section of Nephrology, Department of Internal Medicine, Yale School of Medicine and Yale New Haven Health System, New Haven, Connecticut.
Schaubel DE; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania.
Teitelbaum I; Division of Kidney Diseases and Hypertension, University of Colorado School of Medicine, Aurora, Colorado.
Warady BA; Division of Nephrology, Children's Mercy Kansas City, Kansas City, Missouri.
Neu AM; Division of Pediatric Nephrology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Patel PR; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Piraino B; Department of Medicine, Renal Electrolyte Division, University of Pittsburgh, Pittsburgh, Pennsylvania.
Schreiber M; Home Modalities, DaVita Kidney Care, Denver, Colorado.
Pisoni RL; Arbor Research Collaborative for Health, Ann Arbor, Michigan.
Pokaż więcej
Źródło :
Clinical journal of the American Society of Nephrology : CJASN [Clin J Am Soc Nephrol] 2020 Dec 31; Vol. 16 (1), pp. 154-161. Date of Electronic Publication: 2020 Aug 06.
Typ publikacji :
Journal Article; Research Support, U.S. Gov't, P.H.S.
Czasopismo naukowe
Tytuł :
COVID-19 Clinical Phenotypes: Presentation and Temporal Progression of Disease in a Cohort of Hospitalized Adults in Georgia, United States.
Autorzy :
da Silva JF; CDC COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Hernandez-Romieu AC; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; United States Public Health Service.
Browning SD; CDC COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Bruce BB; CDC COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Natarajan P; CDC COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Morris SB; CDC COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; United States Public Health Service.
Gold JAW; CDC COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Neblett Fanfair R; CDC COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; United States Public Health Service.
Rogers-Brown J; CDC COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Rossow J; CDC COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; United States Public Health Service.
Szablewski CM; CDC COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Georgia Department of Public Health, Atlanta, Georgia, USA.
Oosmanally N; Georgia Department of Public Health, Atlanta, Georgia, USA.
D'Angelo MT; Georgia Department of Public Health, Atlanta, Georgia, USA.
Drenzek C; Georgia Department of Public Health, Atlanta, Georgia, USA.
Murphy DJ; Emory University School of Medicine, Atlanta, Georgia, USA.
Hollberg J; Emory University School of Medicine, Atlanta, Georgia, USA.
Blum JM; Emory University School of Medicine, Atlanta, Georgia, USA.; Georgia Clinical & Translational Science Alliance, Atlanta, Georgia, USA.
Jansen R; Grady Health System, Atlanta, Georgia, USA.
Wright DW; Georgia Clinical & Translational Science Alliance, Atlanta, Georgia, USA.; Grady Health System, Atlanta, Georgia, USA.
Sewell W; Phoebe Putney Memorial Hospital, Albany, Georgia, USA.
Owens J; Phoebe Putney Memorial Hospital, Albany, Georgia, USA.
Lefkove B; Emory Decatur Hospital, Decatur, Georgia, USA.
Brown FW; Georgia Clinical & Translational Science Alliance, Atlanta, Georgia, USA.; Emory Decatur Hospital, Decatur, Georgia, USA.
Burton DC; CDC COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; United States Public Health Service.
Uyeki TM; CDC COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; United States Public Health Service.
Patel PR; CDC COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; United States Public Health Service.
Jackson BR; CDC COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; United States Public Health Service.
Wong KK; CDC COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; United States Public Health Service.
Pokaż więcej
Źródło :
Open forum infectious diseases [Open Forum Infect Dis] 2020 Dec 07; Vol. 8 (1), pp. ofaa596. Date of Electronic Publication: 2020 Dec 07 (Print Publication: 2021).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Autorzy :
Zhang T; Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
Harrison MR; Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
O'Donnell PH; University of Chicago, Chicago, Illinois.
Alva AS; University of Michigan Medical Center, Ann Arbor, Michigan.
Hahn NM; Johns Hopkins University, Baltimore, Maryland.
Appleman LJ; University of Pittsburgh, Pittsburgh, Pennsylvania.
Cetnar J; Oregon Health and Science University Center for Health, Portland, Oregon.
Burke JM; Rocky Mountain Cancer Centers, Aurora, Colorado.
Fleming MT; Virginia Oncology Associates, Norfolk, Virginia.
Milowsky MI; Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina.
Mortazavi A; Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Shore N; Carolina Urologic Research Center, Myrtle Beach, South Carolina.
Sonpavde GP; Dana-Farber Cancer Institute, Boston, Massachusetts.
Schmidt EV; Merck & Co, Inc, North Wales, Pennsylvania.
Bitman B; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.
Munugalavadla V; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.
Izumi R; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.
Patel P; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California.
Staats J; Division of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, North Carolina.
Chan C; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.
Weinhold KJ; Division of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, North Carolina.
George DJ; Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.; Duke Clinical Research Institute, Durham, North Carolina.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Oct 15; Vol. 126 (20), pp. 4485-4497. Date of Electronic Publication: 2020 Aug 05.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Benzamides/*therapeutic use
Pyrazines/*therapeutic use
Urologic Neoplasms/*drug therapy
Aged ; Antibodies, Monoclonal, Humanized/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Benzamides/pharmacology ; Female ; Humans ; Immunotherapy ; Male ; Middle Aged ; Neoplasm Metastasis ; Pyrazines/pharmacology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies